1889 Stock Overview
Sanai Health Industry Group Company Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People’s Republic of China.
Sanai Health Industry Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.087|
|52 Week High||HK$0.28|
|52 Week Low||HK$0.042|
|1 Month Change||7.41%|
|3 Month Change||61.11%|
|1 Year Change||n/a|
|3 Year Change||-51.93%|
|5 Year Change||-77.69%|
|Change since IPO||-95.56%|
Recent News & Updates
What Sanai Health Industry Group Company Limited's (HKG:1889) 35% Share Price Gain Is Not Telling You
Those holding Sanai Health Industry Group Company Limited ( HKG:1889 ) shares would be relieved that the share price...
|1889||HK Pharmaceuticals||HK Market|
Return vs Industry: Insufficient data to determine how 1889 performed against the Hong Kong Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 1889 performed against the Hong Kong Market.
|1889 Average Weekly Movement||27.2%|
|Pharmaceuticals Industry Average Movement||6.2%|
|Market Average Movement||7.0%|
|10% most volatile stocks in HK Market||13.6%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 1889 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 27% a week.
Volatility Over Time: 1889's weekly volatility has increased from 19% to 27% over the past year.
About the Company
Sanai Health Industry Group Company Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People’s Republic of China. It operates through three segments: Pharmaceutical Products, Finance Leasing, and Genetic Testing and Molecular Diagnostic Services. The company provides branded prescription and non-prescription drugs, as well as Chinese pharmaceutical products.
Sanai Health Industry Group Fundamentals Summary
|1889 fundamental statistics|
Is 1889 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1889 income statement (TTM)|
|Cost of Revenue||CN¥27.16m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.0029|
|Net Profit Margin||13.35%|
How did 1889 perform over the long term?See historical performance and comparison
Is 1889 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1889?
Other financial metrics that can be useful for relative valuation.
|What is 1889's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 1889's PE Ratio compare to its peers?
|1889 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: 1889 is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the peer average (6.9x).
Price to Earnings Ratio vs Industry
How does 1889's PE Ratio compare vs other companies in the Hong Kong Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 1889 is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the Hong Kong Pharmaceuticals industry average (9.4x)
Price to Earnings Ratio vs Fair Ratio
What is 1889's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||25.3x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1889's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 1889 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 1889's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 1889's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1889's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Sanai Health Industry Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sanai Health Industry Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Check out Sanai Health Industry Group's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
- Sanai Health Industry Group competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Sanai Health Industry Group performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1889 has high quality earnings.
Growing Profit Margin: 1889's current net profit margins (13.3%) are higher than last year (5.3%).
Past Earnings Growth Analysis
Earnings Trend: 1889 has become profitable over the past 5 years, growing earnings by 66.1% per year.
Accelerating Growth: 1889's earnings growth over the past year (40.5%) is below its 5-year average (66.1% per year).
Earnings vs Industry: 1889 earnings growth over the past year (40.5%) exceeded the Pharmaceuticals industry 16.1%.
Return on Equity
High ROE: 1889's Return on Equity (7.7%) is considered low.
Discover strong past performing companies
How is Sanai Health Industry Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 1889's short term assets (CN¥188.9M) exceed its short term liabilities (CN¥90.1M).
Long Term Liabilities: 1889's short term assets (CN¥188.9M) exceed its long term liabilities (CN¥1.6M).
Debt to Equity History and Analysis
Debt Level: 1889 is debt free.
Reducing Debt: 1889 has no debt compared to 5 years ago when its debt to equity ratio was 7.1%.
Debt Coverage: 1889 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1889 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Sanai Health Industry Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1889's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1889's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1889's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1889's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 1889 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 1889 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sanai Health Industry Group has no CEO, or we have no data on them.
Experienced Management: 1889's management team is considered experienced (2.9 years average tenure).
Experienced Board: 1889's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sanai Health Industry Group Company Limited's employee growth, exchange listings and data sources
- Name: Sanai Health Industry Group Company Limited
- Ticker: 1889
- Exchange: SEHK
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$266.848m
- Shares outstanding: 3.07b
- Website: https://www.1889hk.com
Number of Employees
- Sanai Health Industry Group Company Limited
- Nanyang Plaza
- 7th Floor
- Kwun Tong
- Hong Kong
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/23 00:00|
|End of Day Share Price||2022/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.